Application of formulation technologies in lead candidate selection and optimization

Drug Discovery Today

Volumn 9, Issue 14, 2004, Pages 603-609

  Chaubal, Mahesh V ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

Author keywords

Drug Discovery; Drug discovery support; Formulation; Lead Optimization; Nanoparticles; Techniques Methods

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; ANTINEOPLASTIC AGENT; BETA CYCLODEXTRIN; BETA LACTAM ANTIBIOTIC; CYCLODEXTRIN DERIVATIVE; DRUG; DRUG CARRIER; EXCIPIENT; GAMMA CYCLODEXTRIN; LIPID; LIPOSOME; MACROGOL; MACROGOL 400; PACLITAXEL; POLYMER; POLYSORBATE 80; POVIDONE; TRAZODONE;

COMPLEX FORMATION; DISPERSION; DRUG COATING; DRUG DESIGN; DRUG FORMULATION; DRUG INDUSTRY; DRUG MANUFACTURE; DRUG RESEARCH; DRUG SOLUBILITY; EMULSION; HIGH THROUGHPUT SCREENING; MATHEMATICAL COMPUTING; MICELLE; NANOTECHNOLOGY; NONHUMAN; PARTICLE SIZE; REVIEW; CHEMISTRY; DRUG DELIVERY SYSTEM; METHODOLOGY; PHARMACEUTICS; SOLUBILITY;

CHEMISTRY, PHARMACEUTICAL; DRUG DELIVERY SYSTEMS; PARTICLE SIZE; SOLUBILITY; TECHNOLOGY, PHARMACEUTICAL;

EID: 4344593041     PISSN: 13596446     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6446(04)03171-X     Document Type: Review

References (43)

1. DiMasi J.A., et al. The price of innovation: new estimates of drug development costs. J. Health Econ. 22:2003;151-185
2. Macdonald S.J.F., Smith P.W. Lead optimization in 12 months? True confessions of a chemistry team. Drug Discov. Today. 6:2001;947-953
3. Lipper R.A. How can we optimize selection of drug development candidates from many compounds at the discovery stage? Mod. Drug Discov. 2:1999;55-60
4. Geysen H.M., et al. Combinatorial compound libraries for drug discovery: an ongoing challenge. Nat. Rev. Drug Discov. 2:2003;222-230
5. Ramstrom O., Lehn J.M. Drug discovery by dynamic combinatorial libraries. Nat. Rev. Drug Discov. 1:2002;26-36
6. Bajorath J. Integration of virtual and high-throughput screening. Nat. Rev. Drug Discov. 1:2002;882-894
7. Hariharan M., et al. Reducing the time to develop and manufacture formulations for first oral dose in humans. Pharmacol. Technol. 1:2003;68-84
8. Venkatesh S., Lipper R.A. Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. 89:2000;145-154
9. Yu L.X., et al. Biopharmaceutics classification system: the scientific basis for biowaiver extensions. Pharm. Res. 19:2002;921-925
10. Horspool K.R., Lipinsky C.A. Advancing new drug delivery concepts to gain the lead. Drug Deliv. Technol. 3:2003;34-44
11. Lipinski C.A., et al. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:2001;3-26
12. Kibbey C.E., et al. An integrated process for measuring the physicochemical properties of drug candidates in a preclinical discovery environment. J. Pharm. Sci. 90:2001;1164-1175
13. Cheng A., Merz K.M. Jr., Prediction of aqueous solubility of a diverse set of compounds using quantitative structure-property relationships. J. Med. Chem. 46:2003;3572-3580
14. Chen X.Q., et al. Prediction of aqueous solubility of organic compounds using a quantitative structure-property relationship. J. Pharm. Sci. 91:2002;1838-1852
15. Parrott N., Lave T. Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur. J. Pharm. Sci. 17:2002;51-61
16. Ware E.C., Lu D.R. An automated approach to salt selection for new unique trazodone salts. Pharm. Res. 21:2004;177-184
17. Perng C.Y., et al. Assessment of oral bioavailability enhancing approaches for SB-247083 using flow-through cell dissolution testing as one of the screens. Int. J. Pharm. 250:2003;147-156
18. Krishna G., et al. Development of a parenteral formulation of an investigational anticancer drug, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. Pharm. Dev. Technol. 4:1999;71-80
19. Lee Y.C., et al. An intravenous formulation decision tree for discovery compound formulation development. Int. J. Pharm. 253:2003;111-119
20. Bittner B., Mountfield R.J. Intravenous administration of poorly soluble new drug entities in early drug discovery: the potential impact of formulation on pharmacokinetic parameters. Curr. Opin. Drug Discov. Dev. 5:2002;59-71
21. Sethia S., Squillante E. Solid dispersions: revival with greater possibilities and applications in oral drug delivery. Crit. Rev. Ther. Drug Carrier Syst. 20:2003;215-247
22. Lee T., Lee J. Drug-carrier screening on a chip. Pharmacol. Technol. 1:2003;40-48
23. Thompson D.O. Cyclodextrins-enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Syst. 14:1997;1-104
24. Athanassiou G., et al. Antimicrobial activity of beta-lactam antibiotics against clinical pathogens after molecular inclusion in several cyclodextrins. A novel approach to bacterial resistance. J. Pharm. Pharmacol. 55:2003;291-300
25. Nakamura K., et al. Potential use of cyclodextrins to enhance the solubility of YM466 in aqueous solution. Drug Dev. Ind. Pharm. 29:2003;903-908
26. Uchenna Agu R., et al. Safety assessment of selected cyclodextrins - effect on ciliary activity using a human cell suspension culture model exhibiting in vitro ciliogenesis. Int. J. Pharm. 193:2000;219-226
27. Rao V.M., Stella V.J. When can cyclodextrins be considered for solubilization purposes? J. Pharm. Sci. 92:2003;927-932
28. ten Tije A.J., et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin. Pharmacokinet. 42:2003;665-685
29. Tong X.S., et al. Effect of signal interference from dosing excipients on pharmacokinetic screening of drug candidates by liquid chromatography/mass spectrometry. Anal. Chem. 74:2002;6305-6313
30. Temesi D., et al. Synthesis and evaluation of PEG414, a novel formulating agent that avoids analytical problems associated with polydisperse vehicles such as PEG400. J. Pharm. Sci. 92:2003;2512-2518
31. Odeberg J.M., et al. Lipid drug delivery and rational formulation design for lipophilic drugs with low oral bioavailability, applied to cyclosporine. Eur. J. Pharm. Sci. 20:2003;375-382
32. Porter C.J., Charman W.N. In vitro assessment of oral lipid based formulations. Adv. Drug Deliv. Rev. 50:(Suppl 1):2001;S127-S147
33. Moghimi S.M., Szebeni J. Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42:2003;463-478
34. Pace S., et al. Novel injectable formulations of insoluble drugs. Pharmacol. Technol. 1:1999;116-134
35. Kipp, J.E., et al. (2003) Microprecipitation method for preparing submicron suspensions, US Patent 6607784
36. Chaubal M., et al. Preparation of stable, sterile nanosuspensions for intravenous administration. Proc. Cont. Rel. Soc. Meeting. Vol. 30:2003;. Abstract 227
37. Lockman P.R., et al. Brain uptake of thiamine-coated nanoparticles. J. Control. Release. 93:2003;271-282
38. Merisko-Liversidge E., et al. Nanosizing: a formulation approach for poorly-water-soluble compounds. Eur. J. Pharm. Sci. 18:2003;113-120
39. Merisko-Liversidge E., et al. Formulation and antitumor activity evaluation of nanocrystalline suspensions of poorly soluble anticancer drugs. Pharm. Res. 13:1996;272-278
40. Williams J., et al. Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors. J. Control. Release. 91:2003;167-172
41. Ostrander K.D., et al. An in-vitro assessment of a NanoCrystal beclomethasone dipropionate colloidal dispersion via ultrasonic nebulization. Eur. J. Pharm. Biopharm. 48:1999;207-215
42. Boedeker B.H., et al. J. Clin. Pharmacol. 34:1994;699-702
43. Chen H., et al. A high-throughput combinatorial approach for the discovery of a cremophor EL-free paclitaxel formulation. Pharm. Res. 20:2003;1302-1308